Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Homologous Recombination Deficiency Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1151
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer
Interventions
AZD2281, matching placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
11
States / cities
Berkeley, California • San Francisco, California • West Hollywood, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Mitomycin, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Georgetown, Kentucky • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
Interventions
Olaparib, ASTX727
Drug
Lead sponsor
Pamela Munster
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
Interventions
Talazoparib Tosylate
Drug
Lead sponsor
Melinda Telli
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced May 21, 2026, 5:33 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
Interventions
MOMA-313, Olaparib
Drug
Lead sponsor
MOMA Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Goodyear, Arizona • La Jolla, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions
CB-839, Talazoparib
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)
Interventions
Pamiparib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Athens, Georgia • The Bronx, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Rucaparib, Placebo
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
6
States / cities
San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Interventions
AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
Drug
Lead sponsor
AtlasMedx, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, Adult, Homologous Recombination Deficiency
Interventions
Niraparib, Carboplatin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced May 21, 2026, 5:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases)
Interventions
DSB2455
Drug
Lead sponsor
Duke Street Bio Ltd
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 5:33 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Prednisone
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 5:33 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
47
States / cities
Tempe, Arizona • Tucson, Arizona • San Francisco, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
Interventions
NUV-868, Olaparib, Enzalutamide
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas, Homologous Recombination Deficient-Positive Malignancies Agnostic
Interventions
Lurbinectedin
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Stanford, California • Norwich, Connecticut • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Cisplatin, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Cirtuvivint, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced May 21, 2026, 5:33 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Interventions
Lorigerlimab
Drug
Lead sponsor
Peter Hosein, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 5:33 PM EDT